Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for semaglutide, indicated for long-term weight management. Globally, Novo Nordisk markets semaglutide under the trade name Wegovy for weight loss.
The STEP series of global large-scale clinical studies for semaglutide involved approximately 25,000 overweight and obese subjects, affirming the molecule’s efficacy, safety, and other health benefits in managing adult weight over the long term. The findings indicated that semaglutide outperformed placebo in terms of efficacy, clinical significance, and sustained weight loss, with an average weight loss of 17% (16.8kg) sustained over a period of 16 months. Furthermore, semaglutide was shown to provide multiple health benefits beyond weight loss, including reductions in waist circumference, visceral fat, improvements in blood lipids, and delays in the early progression of diabetes.
In obese patients, semaglutide aids in reducing hunger, increasing satiety, and decreasing food cravings, thus assisting patients in reducing calorie intake and achieving weight loss. The drug has a 7-day half-life and maintains a high homology of 94% with human GLP-1 due to gene recombination technology, enabling once-weekly dosing.- Flcube.com
